Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1393 USD | -1.55% | +0.94% | -76.39% |
04-08 | Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors | CI |
04-03 | NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding | CI |
Valuation
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Capitalization 1 | 16.37 | 42.83 |
Enterprise Value (EV) 1 | 10.94 | 33.88 |
P/E ratio | -1.11 x | -1.54 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | -923,135 x | -2,189,945 x |
EV / FCF | -1,026,095 x | -3,899,619 x |
FCF Yield | -0% | -0% |
Price to Book | 30.2 x | 12.8 x |
Nbr of stocks (in thousands) | 14,749 | 33,201 |
Reference price 2 | 1.110 | 1.290 |
Announcement Date | 24/03/22 | 05/05/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA | - | - | - | - | -11.85 | -15.47 |
EBIT 1 | -5.767 | -3.449 | -4.197 | -2.299 | -11.86 | -15.48 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.657 | -5.147 | -5.447 | -2.861 | -11.95 | -16.5 |
Net income 1 | -6.657 | -5.147 | -5.447 | -2.861 | -11.95 | -16.5 |
Net margin | - | - | - | - | - | - |
EPS 2 | -1.099 | -0.8248 | -0.7964 | -0.4111 | -1.004 | -0.8381 |
Free Cash Flow | - | -1.019 | -0.82 | 0.6351 | -10.66 | -8.688 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 28/02/20 | 28/02/20 | 31/08/20 | 14/05/21 | 24/03/22 | 05/05/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 S1 | 2020 S2 | 2022 S1 | 2022 S2 | 2023 S1 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -1.218 | -8.688 | -6.794 | -7.549 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | -8.641 | -7.855 | -7.613 |
Net income 1 | -1.232 | -1.629 | -8.641 | -7.855 | -7.613 |
Net margin | - | - | - | - | - |
EPS 2 | -0.1800 | -0.2300 | -0.5400 | -0.3000 | -0.2000 |
Dividend per Share | - | - | - | - | - |
Announcement Date | 19/10/20 | 14/05/21 | 11/10/22 | 05/05/23 | 06/12/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 6.68 | 7.09 | 0.62 | 1.99 | - | - |
Net Cash position 1 | - | - | - | - | 5.43 | 8.95 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | -1.02 | -0.82 | 0.64 | -10.7 | -8.69 |
ROE (net income / shareholders' equity) | - | 62.3% | 72.7% | 37.8% | 283% | -863% |
ROA (Net income/ Total Assets) | - | -177% | -623% | -151% | -213% | -129% |
Assets 1 | - | 2.906 | 0.8743 | 1.9 | 5.621 | 12.82 |
Book Value Per Share 2 | -1.270 | -1.270 | -0.8900 | -1.290 | 0.0400 | 0.1000 |
Cash Flow per Share 2 | 0.3600 | 0 | 0.0300 | 0.0100 | 0.3700 | 0.2800 |
Capex | - | - | - | - | 0.04 | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 28/02/20 | 28/02/20 | 31/08/20 | 14/05/21 | 24/03/22 | 05/05/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-76.39% | 6.57M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- NLSP Stock
- Financials NLS Pharmaceutics Ltd.